What's new? Log in Free sign up

Valneva SE (VALN)

Company Profile

Company profile

Ticker

VALN

Exchange

Website

CEO

Mr. Thomas Lingelbach

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • American National • Gilead Sciences • Biogen • Qiagen • Moderna • Bio-Techne • Acorda Therapeutics • BioNTech SE ...

Former names

MONOGRAM ORTHOPAEDICS INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

VALN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva Hosts Investor Day in New York City

Current report (foreign)

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

Bpifrance Participations SA

Deep Track Capital, LP

Bpifrance Participations SA

Bpifrance Participations SA

Deep Track Capital, LP

Bpifrance Participations SA

Financial summary

Financial statements Chart VALN financial data

Quarter (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Valneva SE earnings reports.

Institutional ownership, Q2 2024

VALN institutional ownership history Ownership history

30.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	9	13	-30.8%
Opened positions	2	11	-81.8%
Closed positions	6	0	NEW
Increased positions	1	0	NEW
Reduced positions	1	0	NEW

13F shares	Current	Prev Q	Change
Total value	1.27 bn	4.20 bn	-69.8%
Total shares	21.26 mm	21.62 mm	-1.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Bpifrance Participations	11.62 mm	$365.23 mm	0.0%
PFE Pfizer	9.55 mm	$237.31 mm	0.0%
AlphaCentric Advisors	88.25 k	$648.65 mm	+42.3%
MS Morgan Stanley	1.98 k	$13.87 mm	-63.8%
Ridgewood Investments	550.00	$3.86 mm	NEW
Qube Research & Technologies	22.00	$162.00 k	0.0%
RY Royal Bank of Canada	18.00	$0.00	0.0%
Allworth Financial	7.00	$53.00 k	0.0%
Activest Wealth Management	1.00	$7.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
GAM General American Investors	0.00	-354.36 k	EXIT
AlphaCentric Advisors	88.25 k	+26.25 k	+42.3%
Ironwood Investment Management	0.00	-25.02 k	EXIT
MS Morgan Stanley	1.98 k	-3.50 k	-63.8%
WFC Wells Fargo & Company	0.00	-2.52 k	EXIT
UBS UBS	0.00	-962.00	EXIT
Ridgewood Investments	550.00	+550.00	NEW
Federation des caisses Desjardins du Quebec	0.00	-200.00	EXIT
Advisor	0.00	-150.00	EXIT
Activest Wealth Management	1.00	+1.00	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday

Valneva Reveals Three-Year Antibody Persistence Data For Its Single-Shot Chikungunya Vaccine IXCHIQ

Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults

Valneva Submits Label Extension Application For Its Chikungunya Vaccine, IXCHIQ, To The U.S. FDA To Potentially Include Adolescents And Antibody Persistence Up To 2-Years

To potentially include adolescents and antibody persistence up to two yearsSaint Herblain (France), November 26, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it has

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Valneva Narrows Its 2024 Guidance: Now Expects Total Revenues Of €170M-€180M (Prior €170M-€190M), And R&D Investments Between €65M-€75M

Press releases

From Benzinga Pro

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Saint-Herblain (France), December 4, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announces the publication of an article on the global health and economic burden of mosquito-borne

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Antibody levels remained high at 96% seroresponse in line with the two-year persistence data This long-lasting antibody persistence was comparable in older (65+) and younger adults Saint-Herblain (France), December 3,

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it has

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.